Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phase Holographic Imaging PHI AB (XSAT:PHI) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Phase Holographic Imaging PHI AB Cash Conversion Cycle Related Terms
Phase Holographic Imaging PHI AB Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phase Holographic Imaging PHI AB Cash Conversion Cycle Chart
XSAT:PHI vs ABT, BSX, SYK: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Phase Holographic Imaging PHI AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phase Holographic Imaging PHI AB Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Phase Holographic Imaging PHI AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Phase Holographic Imaging PHI AB's Cash Conversion Cycle falls into.
Phase Holographic Imaging PHI AB Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of 2,066.54 mean?
Phase Holographic Imaging PHI AB (XSAT:PHI) has a Cash Conversion Cycle of 2,066.54 as of Oct. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Phase Holographic Imaging PHI AB and its competitors.
Is Phase Holographic Imaging PHI AB's Cash Conversion Cycle too high?
Phase Holographic Imaging PHI AB's current Cash Conversion Cycle is 2,066.54. The Medical Devices & Instruments industry median Cash Conversion Cycle is 157.71. Phase Holographic Imaging PHI AB's value of 2,066.54 is 1210.3% above this industry median. Overall, Phase Holographic Imaging PHI AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Phase Holographic Imaging PHI AB's Cash Conversion Cycle compare to ABT and BSX?
Phase Holographic Imaging PHI AB's Cash Conversion Cycle of 2,066.54 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 157.71. Phase Holographic Imaging PHI AB's value of 2,066.54 is 1210.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 157.71, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phase Holographic Imaging PHI AB's current Cash Conversion Cycle of 2,066.54 is 1210.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Phase Holographic Imaging PHI AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 157.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phase Holographic Imaging PHI AB's current Cash Conversion Cycle is 2,066.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phase Holographic Imaging PHI AB stock overvalued right now?
Phase Holographic Imaging PHI AB (XSAT:PHI) has a current Cash Conversion Cycle of 2,066.54. The stock's GF Value™ is kr2.80, compared to a current price of kr0.53 — trading 81.1% below its estimated fair value. The current Cash Conversion Cycle is 2,066.54 and 1210.3% above the Medical Devices & Instruments industry median of 157.71. Phase Holographic Imaging PHI AB's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Phase Holographic Imaging PHI AB (XSAT:PHI), the current Cash Conversion Cycle is 2,066.54 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phase Holographic Imaging PHI AB (XSAT:PHI) Overvalued in 2026?
Based on GuruFocus' analysis, Phase Holographic Imaging PHI AB stock appears to be undervalued.
The current stock price of kr0.53 is trading 81.1% below its estimated GF Value™ of kr2.80.
Key valuation signals for XSAT:PHI:
Cash Conversion Cycle: 2,066.54
GF Value™: kr2.80 vs. price of kr0.53 (81.1% below fair value)
Industry Position: 1210.3% above the Medical Devices & Instruments median
No single metric tells the full story. See the XSAT:PHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phase Holographic Imaging PHI AB Business Description
Phase Holographic Imaging PHI AB is a medical device company that develops and markets non-invasive time-lapse imaging instruments used for the quantitative long-term analysis of living cell cultures. The company's commercial HoloMonitor products are based on Quantitative Phase Imaging (QPI) technology, which is used for real-time cell quality evaluation. Geographically, it has presence in Lund, Sweden, with offices in Boston, MA and Winston-Salem, NC.
47GF Score
Get the complete analysis for XSAT:PHI
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:PHI has been successfully added to your 
